Kineta to Present at the Planet MicroCap Showcase 2017
Seattle, WA, April 21, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced the company has been invited to present at the inaugural Planet MicroCap Showcase being held on April 26-28, 2017 at the Planet Hollywood Resort & Casino in Las Vegas, NV. Kineta will be presenting at 1:30 PM EDT/ 10:30 AM PDT on April 27, 2017. Rob Hedequist, President and COO, will provide an overview of the company, as well as the company’s innovative chronic pain and immunooncology programs.
Kineta leadership team members will also be available for one-on-one meetings with investors at the conference. To schedule a time, contact Robert Kraft, Editor-in-Chief, StockNewsNow.com, the conference organizer, at 424-227-9018 or firstname.lastname@example.org. Visit www.PlanetMicroCapShowcase.com for more information.
Kineta, Inc. is an emerging biotech company that fills a void in the biopharmaceutical industry by efficiently advancing first in class immuno-therapies from discovery to proof of concept. Kineta is developing a focused pipeline of novel therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. We actively collaborate with a broad array of private, government, biodefense and industry partners to advance our innovative research. For more information on Kineta, Inc. visit our website, www.kinetabio.com
About the Planet MicroCap Showcase
The Planet MicroCap Showcase brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking in the nation’s #1 destination for meetings and entertainment.
Meet C level executives, investors, financial professionals and industry leaders in the MicroCap stock market for an unequaled experience in networking and dealmaking.
For more information about the Planet MicroCap Showcase, please visit: www.PlanetMicroCapShowcase.com.
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.